ReviewCells2021
Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Clinical stem cell therapy in oral and craniofacial bone regeneration: a systematic review and meta-analysis.Frontiers in bioengineering and biotechnology · 2026Pooled it
- Metabolism of citrate-mediated PI3K-Akt signaling and primary cilium regulates spatiotemporal craniofacial mineralization.Bioactive materials · 2026Article
- Artificial Intelligence and Digital Workflow in Craniofacial Bone Tissue Engineering: From Cone-Beam Computed Tomography (CBCT) to Personalized Bioceramic Implants.Dentistry journal · 2026Review
- Hydrogel Implementing Drug Delivery in Cranial Bone Tissue Engineering.Journal of functional biomaterials · 2026Review
- Knockdown of MEPE Promotes Cranial Defect Repair and Activates the cAMP/PKA Signaling Pathway.Biochemical genetics · 2026Article
- Article
- Assessment of Healing Potential of Alginate and Chitosan-Based Biomaterials for Cranial Bone Defects in Experimental Model.BioMed research international · 2026Article
- A smart nanocomposite bioactive ink for controlled siRNA delivery in calvarial mesenchymal stromal cells as a minimally invasive treatment for craniosynostosis.Regenerative biomaterials · 2026Article
- Application and Progress of Loading Strategies in Bone Tissue Engineering Scaffolds for Bone Regeneration.Bioengineering (Basel, Switzerland) · 2025Review
- Possible Diagnostic and Therapeutic Applications of Bioprinting for Bone Regeneration in Maxillofacial Surgery.Diagnostics (Basel, Switzerland) · 2025Review
- Diagnostic and therapeutic potential of oral cavity-derived exosomes in oral and maxillofacial tissue engineering: current advances and future perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Bone Regeneration in Rat Calvaria Using 3D-Printed Scaffolds with Graded Porosity and In Vitro Degradation.ACS omega · 2025Article
- Advancing Scaffold Architecture for Bone Tissue Engineering: A Comparative Study of 3D-Printed β-TCP Constructs in Dynamic Culture with pBMSC.Journal of functional biomaterials · 2025Article
- Review
- Current State of Knowledge Regarding the Treatment of Cranial Bone Defects: An Overview.Materials (Basel, Switzerland) · 2025Review
- Synthetic Vesicle-Based Drug Delivery Systems for Oral Disease Therapy: Current Applications and Future Directions.Journal of functional biomaterials · 2025Review
- Moldable Alginate/Hydroxyapatite Hydrogel Loaded with Metformin Enhanced Regeneration of the Rabbit Mandibular Defects.Journal of maxillofacial and oral surgery · 2024Article
- Enhanced Bioactivity of Chitosan-Alginate-Riboflavin Liquid-Exfoliated Molybdenum Disulfide Nanosheets for Bone Tissue Engineering Applications.ACS omega · 2024Article
- Shape Memory Polymer Bioglass Composite Scaffolds Designed to Heal Complex Bone Defects.ACS biomaterials science & engineering · 2024Article
- Beyond hype: unveiling the Real challenges in clinical translation of 3D printed bone scaffolds and the fresh prospects of bioprinted organoids.Journal of nanobiotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniofacial bone defects can result from various disorders, including congenital malformations, tumor resection, infection, severe trauma, and accidents. Successfully regenerating cranial defects is an integral step to restore craniofacial function. However, challenges managing and controlling new bone tissue formation remain. Current advances in tissue engineering and regenerative medicine use innovative techniques to address these challenges. The use of biomaterials, stromal cells, and growth factors have demonstrated promising outcomes in vitro and in vivo. Natural and synthetic bone grafts combined with Mesenchymal Stromal Cells (MSCs) and growth factors have shown encouraging results in regenerating critical-size cranial defects. One of prevalent growth factors is Bone Morphogenetic Protein-2 (BMP-2). BMP-2 is defined as a gold standard growth factor that enhances new bone formation in vitro and in vivo. Recently, emerging evidence suggested that Megakaryocytes (MKs), induced by Thrombopoietin (TPO), show an increase in osteoblast proliferation in vitro and bone mass in vivo. Furthermore, a co-culture study shows mature MKs enhance MSC survival rate while maintaining their phenotype. Therefore, MKs can provide an insight as a potential therapy offering a safe and effective approach to regenerating critical-size cranial defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.